Materias: “…United States. Food and Drug Administration Periodicals…”

Materias: “…United States. Food and Drug Administration…”
Enlace del recurso

Materias: “…United States. Food and Drug Administration Rules and practice…”

Tabla de Contenidos: “…""Front Matter""; ""Reviewers""; ""Contents""; ""Abbreviations""; ""1 Introduction""; ""2 Food and Drug Administration Postmarket Surveillance Activities and Recall Studies of Medical Devices""; ""3 Non-Food and Drug Administration Sources of Adverse Event Data""; ""4 Postmarket Surveillance of Medical Devices: Panel Discussion""; ""5 Other Select Topics""; ""Appendix A: Workshop Agenda""; ""Appendix B: Biographic Information on Invited Speakers, Panelists, and Authors of Commissioned Papers""; ""Appendix C: 510(k) Premarket Notification Analysis of FDA Recall Data""…”

Materias: “…United States. Food and Drug Administration Periodicals…”

Materias: “…United States. Food and Drug Administration…”
Enlace del recurso

“…FDA consumer|FDA Consum|Food and Drug Administration consumer…”
Acceso restringido, con credenciales UPSA

Materias:

Materias: “…United States Food and Drug Administration-approved drug…”

Materias:

Tabla de Contenidos: “…Thomas Ten Have""; ""Contents""; ""Abstract""; ""Summary""; ""1 Introduction""; ""2 Incorporating Benefit and Risk Assessment and Benefit-Risk Management into Food and Drug Administration Decision-Making""; ""3 Evidence and Decision-Making""; ""4 Selection and Oversight of Required Postmarketing Studies""; ""5 Synthesis""; ""Appendix A: Other Elements of the Food and Drug Administration Amendments Act""; ""Appendix B: Committee's Letter Report""; ""Appendix C: Open Session Agendas""…”

Tabla de Contenidos: “…Introduction and overview -- Current model for financing drug development : from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary…”

Tabla de Contenidos: “…Introduction and context -- Emerging trends and products of biotechnology -- The current biotechnology regulatory system -- Understanding risks related to future biotechnology products -- Opportunities to enhance the capabilities of the biotechnology regulatory system -- Conclusions and recommendations -- Glossary -- Appendix A: Biographical sketches of committee members -- Appendix B: Agendas of information-gathering sessions -- Appendix C: Requests for information -- Appendix D: Congressionally defined product categories that the U.S. Food and Drug Administration regulates…”

Tabla de Contenidos: “…The trouble with time -- Eugenic conceptions I : ticking time bombs -- Eugenic conceptions II : useless eaters -- A little brain pathology -- Informed consent and the dawn of the public relations era -- The American Psychiatric Association Task Force -- The making of an American activist -- The ECT industry cows the media -- Long strange trip : ECT and the food and drug administration -- The Committee for Truth in Psychiatry -- Anecdote or evidence? …”

“…It presents the latest findings on the toxic effects of BPA, diseases that may be related to bisphenol exposure, and the regulations of the US Food and Drug Administration, European Food Safety Authority, and European Union…”

Tabla de Contenidos: “…Biomedical Politics -- Copyright -- Preface -- Acknowledgments -- Contents -- Introduction -- References -- Unproven AIDS Therapies: The Food and Drug Administration and DDI -- THE DRUG REGULATION PROCESS -- The Drug Approval Process Today -- Speeding Up the Process: The "Bush Initiative -- Prelicensing Availability -- PARALLEL TRACK -- PARALLEL TRACK: PROS AND CONS -- The Food and Drug Administration -- The Research Community -- The AIDS Activists -- Other Consumer Interests -- EARLY RELEASE OF DDI -- MOTIVATIONS -- Bristol-Myers -- The Food and Drug Administration -- The National Institutes of Health -- The Activists -- CONCLUSIONS -- NOTES -- REFERENCES -- Commentary -- LEON EISENBERG -- Commentary -- PETER F. …”